Portfolio company
ALKemist BIO
Country not known yet
Raised
Not known yet
Latest stage
Not known yet
Rounds recorded
Not known yet
Backed by
4 investors
Sectors
About
This biotechnology company develops cellular immunotherapies targeting the ALK oncogene to treat patients with ALK-positive tumours.
SourceFunding history · 0
No rounds recorded yet. The agent looks for them over time.
Similar companies
Appia Bio
This company develops engineered allogeneic cell therapies from hematopoietic stem cells for cancer patients.
ALXO
This biopharmaceutical company develops immune system therapies to treat cancer patients with solid tumors and hematologic malignancies.
AilseBio
This biotech company develops artificial intelligence to discover therapy-induced antigens for cancer vaccines and immunotherapies for the healthcare sector.
Alceus
This company develops a platform that uses artificial intelligence to design therapeutic proteins and program immune cells for clinicians and researchers treating solid tumours.
BRENUS PHARMA
This company develops allogeneic cancer immunotherapies for patients with solid tumors using a proteomics-guided platform that mimics tumor cell resistance and escape mechanisms.
Akamis Bio
This clinical-stage oncology company develops intravenously administered immunotherapies to treat solid tumours, specifically targeting patients living with colorectal cancer.
OverT
This biotechnology company develops engineered cell therapies for the treatment of solid tumours in cancer patients.
Bioarchitech
This company develops viral and RNA immunotherapies designed to help the immune systems of cancer patients target and destroy tumours.